A House report raises questions about the overly-close relationship between the FDA and Biogen, which led to approval of the Alzheimer's disease drug Aduhelm, despite significant evidence the drug did…
A new study warns that the FDA fails to rely on previous experience in dealing with the approval of drugs with questionable effectiveness, which could erode public trust.
Two powerful House committee chairs are calling on the FDA to provide a raft of information on how and why it approved the controversial new Alzheimer's drug Aduhelm.
The FDA's Acting Commissioner has asked the Office of the Inspector General to investigate the agency's controversial decision to approve the new Alzheimer's disease drug, Aduhelm, following a wave of…
Two members of an FDA advisory committee have resigned in protest over the approval of a new Alzheimer's disease drug, which many critics say shows no evidence of actually being…
The FDA faces criticism for the rushed approval of a new Alzheimer's disease drug, which its own advisors say has not been shown to be effective.
Public Citizen is calling for an investigation into the relationship between the FDA and Biogen after the agency helped shepherd an experimental Alzheimer's disease drug through its approval process despite…
Tysabri PML rates are on the decline after preventative guidelines went into effect, according to a new study.
European regulators say they have positively confirmed that the recently recalled MS drug Zinbryta had health risks that outweighed any potential benefits, indicating that causes of severe brain inflammation were…
A new study indicates that Zinbryta side effects were so severe it could have never become a major drug product, raising questions as to why it was approved when there…
